Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. - Wikidata - wikimedia - TriplyDB

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.

http://www.wikidata.org/entity/Q34533041

about

Co-evolution of the MHC class I and KIR gene families in rhesus macaques: ancestry and plasticity Antibody responses to envelope glycoproteins in HIV-1 infection Broadly Neutralizing Antibodies for HIV Eradication Perspectives for immunotherapy: which applications might achieve an HIV functional cure?Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.Strategies to guide the antibody affinity maturation process Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.Animal models in HIV-1 protection and therapy Can immunological principles and cross-disciplinary science illuminate the path to vaccines for HIV and other global health challenges?Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in Macaques A new hypothesis on HIV cure.Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.Contrasting antibody responses to intrasubtype superinfection with CRF02_AG.Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary.Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.Rare Control of SIVmac239 Infection in a Vaccinated Rhesus Macaque.Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the Setting of Peripartum Antiretrovirals.Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.A single gp120 residue can affect HIV-1 tropism in macaques.The HIV-1 transmission bottleneck.Broadly neutralizing antibodies in HIV-1 treatment and prevention

P2860

Q26797239-838D197F-A0E5-49B4-8B87-4033F44B47FA Q26991572-D188C8D1-DFD0-4BFB-8753-066EFC5095AB Q28073939-DECD8738-2B63-4082-9FA2-9A1C7CC35101 Q28078726-78BD0315-410A-4EC2-84C5-A124D151D199 Q30145646-3975305C-30BD-4A38-99EB-E36EAD802DFC Q33786447-2407A252-87EF-43D0-8072-009B516939F5 Q34499013-054E3205-228C-4934-B552-053CD1DC7D99 Q34540352-E39E597D-1B62-40C1-A7AF-E25BF1D8948F Q35569901-FDC13300-7360-4F89-80D2-FB8C77D23C5C Q35685300-2D21AFC6-85E8-460D-8C5A-CD5A09B8C01D Q35760486-18522FD9-AFF8-4F2E-B62E-5438DECF5081 Q35817106-D3A93146-79AD-4768-ABD4-E7B88C05C05A Q35920037-D2E9E636-D809-4942-9573-943B04C0A69F Q35923859-50C12AF7-762F-4FFA-B371-DAB03277415E Q35974269-51719415-5B32-400D-A159-AEAB3DC6BF36 Q35974961-A9EEE627-11EF-4CF4-B940-414A797E28A6 Q36028475-7B3551D0-C928-41BB-B2F1-E8F1E8808834 Q36053810-D90D8DF0-62AE-4D5A-946F-3ECE5851E098 Q36105672-A2EC6957-EE6C-4978-AA94-CE484336A8E2 Q36159067-10190154-5148-4F7B-A88B-CC39BA9C1134 Q36184762-22B073C4-8DE5-4433-AF81-72045B82256C Q36306344-95BAE83D-CB33-4CC8-8F06-16616C4243D5 Q36515149-D5D75227-FD74-4074-9560-D39E79637278 Q36601983-ADBCA6E0-80A4-414E-8610-BD810889E15B Q36961578-8F4F09A7-A354-436B-9FF7-A7FCC24107AC Q38542411-1FDC5F3E-CE45-48C7-AE80-E6C247A5F582 Q38717198-6E3A8B55-43A9-4757-8151-9B7C50F77707 Q38725480-CB7816CC-3FA1-4C71-94F0-2159943D5C8B Q38786450-09DBB65E-C45F-4BB5-9490-0C3DAB934C03 Q38968180-42FD94C0-F010-447F-8D20-19871DA19E01 Q39407795-9A30D977-2F3E-40DE-9F7A-DEB23EAADF98 Q40178574-D6C25D49-3367-4463-A404-406F50692B38 Q40449526-8A6B71FE-B4E8-42CB-87F5-039C1FA8AE47 Q41930708-BDB095A1-1CAA-4D03-8D28-B54E0449BFE9 Q42314454-0E56E8BE-A954-459B-9947-7903EFBA7277 Q57815702-3790226C-9AC9-44D2-B2DB-1E4659E8AB82

P2860

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.

http://www.wikidata.org/entity/Q34533041

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Enhanced HIV-1 immunotherapy b ...... target virus escape variants.

@ast

Enhanced HIV-1 immunotherapy b ...... target virus escape variants.

@en

Enhanced HIV-1 immunotherapy b ...... target virus escape variants.

@nl

type

label

Enhanced HIV-1 immunotherapy b ...... target virus escape variants.

@ast

Enhanced HIV-1 immunotherapy b ...... target virus escape variants.

@en

Enhanced HIV-1 immunotherapy b ...... target virus escape variants.

@nl

prefLabel

Enhanced HIV-1 immunotherapy b ...... target virus escape variants.

@ast

Enhanced HIV-1 immunotherapy b ...... target virus escape variants.

@en

Enhanced HIV-1 immunotherapy b ...... target virus escape variants.

@nl

P1433

Q34533041-898FD543-20C4-428E-88CE-FD509FFE39C4

P1476

Q34533041-BE6D7A82-C032-4EA1-A640-9508C9D7637E

P2093

Q34533041-02586069-ED8D-47D1-8B5A-78DFC769CBFC

Q34533041-0847A4FC-0E65-4C72-97A6-B6CCD16E4FBD

Q34533041-1EF697A1-FC65-4ACD-A9DE-093F9B559D8B

Q34533041-413387B8-A2C7-4141-8302-323280222B96

Q34533041-5C0B1360-7383-4147-B82A-7FDE82E0BCF9

Q34533041-7AD14E56-A1C4-4454-ADD1-EC892BCB926D

Q34533041-8274BB84-8218-4DEE-9553-8516012A97FA

Q34533041-9DDD1D12-0E13-436E-B049-0F5BF96AE9B1

Q34533041-A0DE7176-6C09-439F-B1EB-EA2F438037DF

Q34533041-A8423244-6A45-49CB-9717-91FC65082A9A

P2860

Q34533041-065AD7A0-A287-449D-9948-BEB83A48E8B6

Q34533041-0BC71051-3F3D-40FB-86BD-AA1EB41C027D

Q34533041-0EEB03F9-533A-433E-A868-1A457510933E

Q34533041-197C46DB-EB69-47A1-BDEF-6F7A3E5B8ECD

Q34533041-1CEE1F15-0390-4C8F-A50F-F4BBE8EBE5DF

Q34533041-1FB56877-EB84-4028-920C-C1AF2E3B1F97

Q34533041-2317411E-CF78-42F6-B722-67138F0B0A6C

Q34533041-294F9AB5-6CA7-4769-9629-346EB16F3056

Q34533041-2B79FE49-C06C-48C3-8DB4-312317EA77AA

Q34533041-3C6CFFCF-EA08-4A80-AAF0-8D4C478C49ED

P304

Q34533041-AA34D6B4-F51E-4DED-A934-013D542C0520

P31

Q34533041-B76FEC95-04B2-4A6C-BA85-B3053417BE79

P356

Q34533041-9126D9A3-9979-4F87-9E0F-F3947B2FCBF1

P407

Q34533041-F71A47A1-C71B-4948-9BB4-0408ED338B2D

P433

Q34533041-A98918D6-4F14-4994-847E-7A2A979B86E4

P478

Q34533041-C4D448F7-FC0F-43AE-AABC-5FF7507D3265

P50

Q34533041-26747951-5C93-4C10-BE76-2C6B4C0AA5C1

Q34533041-33235759-B57F-4343-BBA4-FEFE14F3B4FB

Q34533041-6A224E33-DFAA-4A19-B8DD-A39778630A5E

Q34533041-BB62F695-00E3-4CCE-AA90-0C8098E05A11

Q34533041-C054F247-F8CA-4472-B674-1E3DC67B3016

P577

Q34533041-F6A55A11-0C7A-41AB-A172-E3C728223C7D

P5875

Q34533041-DB837623-7A9A-445D-9636-0CB70C6FA7C1

P698

Q34533041-53AFB93A-6063-49C6-8A0E-2BE87FC3AC5B

P921

Q34533041-5093DBF5-E4B2-431F-BAA4-D82A4DB674BF

Q34533041-59F2785B-A045-4D72-901C-D28B1FB4ED63

Q34533041-A3EB5B42-0748-400C-AA45-29EEB2C306B6

P932

Q34533041-7DF13CBE-CDA2-4D68-A7C9-38F2E18C1EE3

P356

P1433

Journal of Experimental Medicine

P1476

Enhanced HIV-1 immunotherapy b ...... target virus escape variants.

@en

P2093

Anthony P West

http://www.w3.org/2001/XMLSchema#string

Ariel Halper-Stromberg

http://www.w3.org/2001/XMLSchema#string

Cassie Liu

http://www.w3.org/2001/XMLSchema#string

Clara Lehmann

http://www.w3.org/2001/XMLSchema#string

Constance Williams

http://www.w3.org/2001/XMLSchema#string

Florian Klein

http://www.w3.org/2001/XMLSchema#string

Gunilla B Karlsson Hedestam

http://www.w3.org/2001/XMLSchema#string

Joshua A Horwitz

http://www.w3.org/2001/XMLSchema#string

Lilian Nogueira

http://www.w3.org/2001/XMLSchema#string

Malcolm A Martin

http://www.w3.org/2001/XMLSchema#string

P2860

Antibodies in HIV-1 vaccine development and therapy

Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens

Conserved structural elements in the V3 crown of HIV-1 gp120

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes

Antibody neutralization and escape by HIV-1

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Broad neutralization coverage of HIV by multiple highly potent antibodies

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

P304

2361-2372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20141050

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

211

http://www.w3.org/2001/XMLSchema#string

P50

Pamela J. Bjorkman

Michel C. Nussenzweig

Gerd Fätkenheuer

P577

2014-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268230034

http://www.w3.org/2001/XMLSchema#string

P698

25385756

http://www.w3.org/2001/XMLSchema#string

P921

P932

4235636

http://www.w3.org/2001/XMLSchema#string